Objectives. To measure the frequency of and risk factors for rheumatic manifestations after chikungunya virus (CHIKV) infection and to assess their impact on quality of life (QoL).
Introduction
Chikungunya virus (CHIKV) infection is caused by an arboviral alphavirus transmitted to humans by Aedes mosquitoes. In 2005, an outbreak of CHIKV infection occurred on the islands of the Indian Ocean. On Reunion Island, 38.2% of the 785 000 inhabitants were infected between March 2005 and September 2006 [1] and several hundreds of cases were consequently reported in mainland France among returning travellers [2] . Seventy per cent of these cases were reported not to be cured 4 months after onset of CHIKV infection [3] . Rheumatic manifestations persisting several months or years after acute infection have been previously reported [48] . The persistence of symptoms without any tool to predict either healing or clinical relapses may be associated with severe distress and affect health-related quality of life (QoL). In 2009, a study among residents of Reunion Island suggested that some dimensions of QoL might still be affected after an average of 17 months [6] .
The impact of rheumatic diseases on QoL has been studied for rheumatic diseases like OA, RA and AS, using generic and disease-specific self-report questionnaires [910] . Generic instruments allow comparison with norms issued from the general population when available. Arthritis-specific instruments are acceptable for post-CHIKV rheumatism whose symptoms, mode of evolution and unpredictable duration are close to those of inflammatory arthritis. To measure the frequency of and risk factors for rheumatic manifestations after CHIKV infection and to assess their long-term impact on QoL, we conducted a cohort study among imported cases diagnosed in mainland France from March 2005 to 2007.
Methods
In 2005, a laboratory-based surveillance system of imported cases of CHIKV infection was set up in mainland France to allow the detection and management of cases in areas with the potential vector Aedes albopictus to prevent transmission [11] . Persons eligible for the study were identified through this surveillance system [2] .
A patient was a person with clinical symptoms of CHIKV infection confirmed by the presence of CHIKV-specific IgM antibody or detection of CHIKV using RT-PCR from March 2005 to 2007. The patients' postal addresses and telephone numbers were obtained by their microbiologists or physicians after oral consent. In mid-December 2007, a self-administered standardized questionnaire was mailed to 509 patients with a known address. The study was approved by the Comité Consultatif sur le traitement de l'information en matiè re de recherche dans le domaine de la santé and by the Commission nationale de l'informatique et des liberté s.
Data were collected on demographic characteristics and clinical manifestations of CHIKV infection: during the acute stage, from the acute stage to time of assessment and in the previous week. Acute stage was defined as the presence of arthralgia and fever lasting for <30 days after symptom onset. Relapse was defined as the reappearance of arthralgia after a substantial decrease in intensity or after a symptom-free period of at least 1 week.
Current health status in terms of generic and specific QoL, mental health and comorbidity were determined using the following:
The 36-item short-form health survey (SF-36) questionnaire [12] is a generic health status questionnaire. It includes eight dimensions scored from 0 (worst) to 100 (best QoL). SF-36 physical and mental components are two weighted combinations of its eight dimensions with physical functioning, role limitations due to physical health problems and bodily pain dominant in the physical component, and mental health, role limitations due to emotional problems and social functioning dominant in the mental component. The short form of the the Arthritis Impact Measurement Scales 2 (AIMS2-SF) [13] is a specific measure of health status developed and validated for rheumatic diseases, including five dimensions from 0 (best) to 10 (worse QoL). The General Health Questionnaire (GHQ-12) [14] is a measure of mental health and psychological distress with 12 items rated in four modalities (03). It results in one unique score from 0 (worst) to 100 (best psychological health). The Functional Comorbidity Index (FCI) [15] has been developed to include all comorbidities associated with deterioration of physical QoL. It is scored from 0 to 7 and allows counting the number of comorbidities.
Statistical analyses
The association between recovery and explanatory variables was calculated by relative risk (RR) and 95% CI (univariate analysis). We conducted a multivariate survival analysis for interval-censored data using a backward procedure to estimate the time to full recovery depending on explanatory variables selected with a P < 0.1 in the univariate analysis. A survival curve was built using the iterative Turnbull's procedure [16] For the QoL part of the study, quantitative and qualitative variables were described using mean (S.D.) and percentages, respectively. QoL scores were presented by dimension. Data from a French national survey conducted with a random sample population of 35 000 persons [19] were used as reference values for SF-36. SF-36 dimensions were compared with the general population samplematched for age and gender categories. QoL scores were presented according to the change in health status since disease onset. Patients QoL scores in those who have recovered and not recovered were compared using Student's t-test and 2 -test, respectively. The association of QoL score with comorbidity and with the presence of rheumatic diseases like OA and osteoporosis was analysed by Spearman's correlation coefficient and Student's t-test, respectively. QoL levels were studied according to disease duration, duration of acute stage and residual symptoms in the past 7 days. In multivariate linear regression models, factors associated with QoL at follow-up in univariate analysis included age at disease onset, disease duration, duration of acute stage, comorbidity score, presence of other rheumatic diseases and current residual symptoms were studied. Statistical significance was set at 0.05 and analyses were run using SAS 9.1.
Results
Seven hundred and fourteen patients with a CHIKV infection diagnosed from March 2005 to 2007 were eligible in the laboratory-based surveillance system. Postal addresses were available for 509 (71%) patients. The overall participation rate was 77% (391/509).
Two-hundred and nine (53.5%) patients were females. The mean age at CHIKV infection onset was 50.2 years (median 52 years; range 682 years) and did not differ between men and women (49.6 vs 50.9). The age distribution was <30 years 10% (n = 40), 3049 years 32% (n = 126), 5069 years 49% (n = 190) and 570 years 9% (n = 35).
During the acute stage, 96% (360/376) reported fever, 99% (383/389) arthralgia, 93% (350/377) joint stiffness and 74% (276/373) joint swelling. Small joints of the hands, ankles and feet were most often affected. The duration of the acute stage was <8 days for 50% (171/343) and 830 days for 50% (172/343). At the time of assessment, the mean time since onset was 22.9 months (median 23.4 months; range 11.840 months). The distribution of the 391 patients by 6-month period since onset of symptoms was none (06 months), 1 (612 months), 45 (1218 months), 198 (1824 months), 129 (2429 months) and 18 (530 months).
The presence of comorbidity was reported by 60% (227/377) patients, most often degenerative disc disease (52%), arthritis (34%) and depression (23%) ( Table 1) . They reported, on average, one comorbidity with an FCI score of 1.1 (±1.4). A comorbidity was reported for 62.5% (125/200) of women and 57.6% (102/177) of men (P = 0.33). Patients reporting a comorbidity were significantly older at disease onset than those not reporting (mean age 54.2 vs 44.7, P < 10 À3 ). Overall, 176 (45%) patients considered themselves recovered and 103 (26%) did not know if they had recovered. The latter did not differ from the 112 patients having not recovered regarding gender, age, comorbidity at time of assessment, delay between onset of symptoms and assessment, duration of the acute stage, presence of fever, arthralgia, stiff or swollen joints during the acute stage or in the previous 7 days and relapses during the studied period. They were therefore included in the analysis as patients not having recovered. Consequently, 215 (55%) patients were considered as not recovered at the time of assessment.
The duration of symptoms was known for 338 (86%) patients. The median interval of the duration of symptoms was 69 months (range <15 days to >33 months). ]. The probability for full recovery at 1 year was 0.39 (Fig. 1) .
Relapses of arthralgia were reported for 72% (274/381) patients. The number of relapses was documented for (Table 2) . Age, duration of the acute stage and presence of swollen joints at the acute stage were included in the multivariate model. Comorbidity variables statistically significant in the univariate analysis were not included because they were collected at the time of assessment.
In the multivariate analysis, the probability of recovery was lower in the 30-to 49-year age group [hazard ratio (HR) = 0.51 (0.320.83)] and in the 50-to 69-year age group [HR = 0.37 (0.230.59)] than in the <30-year age group. The duration of the symptoms increased by 49 and 63%, respectively, in those two age groups. Having a duration of the acute stage longer than 15 days increased the duration of the symptoms by 49% and decreased the probability of recovery [HR = 0.51 (0.350.76)].
The QoL scores at follow-up were severely affected whatever the instrument used ( Table 3 ). The SF-36 showed low scores in some dimensions, ranging from 75.8 in physical functioning down to 49.0 in vitality. Physical and mental components were low at 46.1 and 43.4, respectively. The AIMS2-SF was also affected (higher scores) mainly in symptoms and psychological and social dimensions, and the GHQ-12 showed a decreased score at 61.7. At the time of assessment, 176 recovered patients had a QoL significantly higher than the 215 not recovered (P < 0.001), but 25% of them still had a lower QoL. In recovered patients (87 females and 84 males), there were no significant differences of SF-36 scores compared with the general age-and gendermatched population of 1956 women and 1661 men. An exception of better bodily pain in both genders (P = 0.03 and 0.02), better physical functioning in women (P < 0.001) and lower emotional role in men (P = 0.044) was observed (Table 4) . For the 215 non-recovered patients, there was a large decrease of about 20 points in physical and mental functioning (P < 0.001) and of about 10 points in social domains, particularly in younger (aged 4554 years) patients.
There were significant correlations (P < 0.0001) of FCI with all dimensions of SF-36 (r = À0.28 to À0.37), AIMS2-SF (r = 0.220.35) and GHQ-12 (r = À0.24). The 78 patients reporting OA had a lower QoL by 0.61.9 points per dimension of AIMS2-SF and by 617 points of SF-36. Mental health by GHQ12 did not differ significantly. Patients with osteoporosis (n = 19) did not differ significantly from those without osteoporosis. The duration of the CHIKV infection was significantly correlated (P < 0.0001) with all dimensions of SF-36 (r = À0.21 to À0.47), AIMS2-SF (r = 0.090.43) and GHQ-12 (r = À0.23). A longer duration of the acute stage was associated with a lower SF-36 physical score, mental limitation and general health, with a lower GHQ-12 score and with a higher (worse) AIMS2-SF physical score. Regarding symptoms reported in the 7 days before assessment, swollen joints were statistically associated with all dimensions of all instruments (P = 0.04 to <0.001), while other symptoms like pain and joint stiffness were associated with physical dimensions only (P = 0.034 to <0.001).
In multivariate linear regression, factors associated with lower (worse) SF-36 QoL scores were older age (P = 0.010.002), lack of recovery (P < 0.0001), presence of comorbidity (P = 0.005 to <0.0001) and longer duration of acute stage (P = 0.01 to <0.0001). 
Discussion
Among imported confirmed cases of CHIKV infection in mainland France, we studied the presence of rheumatic   FIG. 1 Cumulative probability of patients reporting recovery (Turnbull's method), CHIKV infection and QoL study, France.
manifestations after the acute stage of disease and particularly their impact on QoL. At median 23.4 months from disease onset, 55% of the patients considered themselves not to have recovered from CHIKV infection. Factors associated with a longer disease duration were older age and an acute stage >15 days. Whatever the duration of the disease and the duration of the acute stage, patients with chronic manifestations of CHIKV infection have a deteriorated QoL as assessed by generic (SF-36), mental (GHQ-12) and specific (AIMS2-SF) tools. Recovered patients seemed to have a QoL equivalent to the general population whatever the duration of the acute stage. Interestingly, age and gender seemed to have little impact on QoL, as opposed to the general population, where it is known to be lower in women and elderly people. One might infer that the impact of CHIKV infection could be more important in men and younger people. However, the high proportion of comorbidities has a marked impact in all explored dimensions.
To our knowledge, this is the first study combining indepth investigation of generic, mental and specific QoL among a large number of CHIKV-infected patients with a long follow-up period (2 years on average). Moreover, QoL TABLE 2 Factors associated with reported recovery of the CHIKV infection (univariate analysis), CHIKV infection and QoL study, France scores among CHIKV-infected patients were compared with those of the French general population.
The study has some limitations. First, the questionnaires were self-administered, patients had no medical examination and recovery was self-perceived.
Non-recovered patients may have been more likely to participate to the study. Secondly, the comorbidities may have impacted QoL before CHIKV infection occurrence, but this was not measured and the modifying effect of CHIKV infection cannot be quantified. Arthritis being the [5] . In our study, older age was also significantly associated with a long duration of symptoms. The proportion of non-recovery in our study (55%) is close to the 57 and 59% of patients experiencing rheumatic manifestations in two studies [5, 8] carried out in populations with similar mean age. Two other studies [6, 7] found nonrecovery rates of 44% in a young population (mean age 42 years) and 64% in an older population (mean age 58 years).
In our study, longer duration of the acute stage was also associated with duration of the symptoms. In one study on Reunion Island [23] , overall 32% of the CHIKV patients had rheumatic manifestations at 9 months follow-up: 17% if the duration of the acute stage was 414 days and 84% if >14 days [RR 4.95 (3.48, 7.05)]. Relapses of joint pain were reported by 72% of the patients, and the presence of comorbidity, joint stiffness and swelling during the acute stage and a longer duration of the disease (>3 months) were associated with relapses. The occurrence of relapse in our study is high compared with other studies [5, 7, 23, 24] and might be due to a longer follow-up and to a different definition of relapse.
QoL impairment in CHIKV-infected patients has similar levels as frequent rheumatic diseases like OA [25] or RA [26] , illustrating the severity of the long-lasting QoL impact of the disease. A study on Reunion Island having explored QoL using the SF-12 questionnaire only found a decrease in physical but not in mental domains in confirmed CHIKV-infected patients compared with uninfected individuals matched for age, gender and area of residence [6] . These results are consistent with ours for physical domain, but our data revealed a persistent impact on mental health domain in patients diagnosed in mainland France.
Recommendations can be formulated in the light of these findings. Medical follow-up of CHIKV-infected patients until full recovery is important in order to ensure a return to normal perceived health and QoL. Paying attention to comorbidity may help anticipate a potential great deterioration in their QoL. Patients can be informed that return to normal will progressively occur in most cases and could benefit from sharing of information about the possible chronic symptoms and the unpredictable course of the disease. Support should be given for the potential depression and anxiety that these elements of CHIKV infection can provoke.
Rheumatology key messages
. Older age and previous comorbidities predict a worse QoL for chikungunya-infected patients. . Chikungunya-infected patients should be offered mental health support for potential chronic sequelae.
